These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18955449)

  • 1. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
    Judson IR
    J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
    [No Abstract]   [Full Text] [Related]  

  • 2. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
    Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
    J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumors, version 2.2014.
    von Mehren M; Randall RL; Benjamin RS; Boles S; Bui MM; Casper ES; Conrad EU; DeLaney TF; Ganjoo KN; George S; Gonzalez RJ; Heslin MJ; Kane JM; Mayerson J; McGarry SV; Meyer C; O'Donnell RJ; Pappo AS; Paz IB; Pfeifer JD; Riedel RF; Schuetze S; Schupak KD; Schwartz HS; Van Tine BA; Wayne JD; Bergman MA; Sundar H
    J Natl Compr Canc Netw; 2014 Jun; 12(6):853-62. PubMed ID: 24925196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I
    Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
    Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT mutations in GIST.
    Fletcher JA; Rubin BP
    Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A; Bui B
    Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 14. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
    Xu J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative treatment of gastrointestinal stromal tumors.
    Fernandes Gdos S; Blanke CD; Freitas D; Guedes R; Hoff PM
    Oncology (Williston Park); 2009 Jan; 23(1):54-61. PubMed ID: 19283922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
    Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
    Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.